HOME >> BIOLOGY >> NEWS
Researchers unveil strategy for creating actively-programmed anti-cancer molecules

The new study, which was published July 5 in an advanced, online edition of the Proceedings of the National Academy of Sciences, achieved a significant enhancement of the treatment of metastatic breast cancer in animal models. The study showed the new hybrid compound remained in circulation for a week. In comparison, the small molecule drug was cleared in a matter of minutes.

"Although the study focused specifically on breast cancer, these new findings could have broad application in the treatment of a number of other cancers, potentially increasing the efficacy of a number of existing or undeveloped small molecule therapies," said Subhash C. Sinha, Ph.D., associate professor in the Scripps Research Department of Molecular Biology and the Skaggs Institute for Chemical Biology, who led the research with Scripps Research President Richard A. Lerner, M.D., Lita Annenberg Hazen Professor of Immunochemistry, Cecil H. and Ida M. Green Chair in Chemistry, and a member of the Skaggs Institute for Chemical Biology.

In the study, the scientists created what is known as a "chemically programmed antibody" by using small cell-targeting molecules and a non-targeting catalytic monoclonal aldolase antibody in a novel self-assembly strategy. Antibodies are proteins produced by immune cells that are designed to recognize foreign pathogens harmful to the body; monoclonal antibodies are produced in the laboratory from a single cloned B-cell, the immune system cell that makes antibodies.

"By bringing together chemistry and biology, our approach provides a way to break the traditional one antibody-one target axiom of immunochemistry," said Lerner. "This new hybrid technology offers great possibilities for the enhanced treatment and diagnosis of a variety of diseases, including cancer."

Preventing Breast Cancer Metastasis

In the study, the researchers used the unique assembly strategy to create a novel compound to combat metastatic br
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
11-Jul-2006


Page: 1 2 3

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 11, 2018 , ... ODSC Europe 2018 - one of ... attendance at the event from September 19-22. , As Europe’s largest applied data ... 10 tracks and 4 days. Attendees were given key insights and hands-on training ...
(Date:10/11/2018)... ... October 11, 2018 , ... Better lives through a healthy ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Institute, a public-private partnership launched in March ... workforce development in the United States. Biopharmaceuticals are important because they treat and ...
(Date:10/5/2018)... ... October 04, 2018 , ... CallTower Inc., ... was present at Microsoft Ignite 2018, in Orlando, Florida, when Microsoft made a ... a statement about the new direction of Skype for Business Online, outlining the ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... , ... September 28, 2018 , ... ... (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood ... With the partnership, PMLS will promote and offer the GlycoMark test to its ...
(Date:9/27/2018)... ... 26, 2018 , ... NDA Partners Chairman Carl Peck, ... and in vitro diagnostic device expert with more than 28 years of experience ... as an Expert Consultant. Her experience includes leadership roles in regulatory strategy, quality ...
(Date:9/27/2018)... BOSTON (PRWEB) , ... September 26, 2018 , ... ... conference. Medable is a platform that aims to build the first human digitome, ... clinical trial and real-world data through a seamless integration of all data sources. ...
(Date:9/27/2018)... (PRWEB) , ... September 27, 2018 , ... ... York City, Everwell Health Solutions and SureAdhere Mobile Technology, Inc. announced they will ... medication monitoring in the battle against tuberculosis (TB) and other diseases. These two ...
Breaking Biology Technology:
Cached News: